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Summary
The AML1/CBF transcription factor complex, a frequent target of chromosomal translocations in leukemia, is essential for
the generation of definitive hematopoietic stem cells. Paradoxically, expression of the acute myeloid leukemia-associated
AML1-ETOfusionprotein inmiceresultsnot in leukemia,but inembryonic lethalityduetoanabsenceofnormalhematopoiesis.
To bypass the embryonic lethality, we generated a mouse strain with a conditional AML1-ETO knockin allele that contains a
loxP bracketed transcriptional stop cassette 5 to the AML1-ETO fusion site. Activation of this allele in vivo by Cre-mediated
recombination resulted in an enhanced replating efficiency of myeloid progenitors, but it did not block their differentiation,
nor was it sufficient to induce leukemia. However, induction of cooperating mutations resulted in the development of an acute
myeloid disease that mimicked many of the features of human AML1-ETO-expressing leukemia.
Introduction poietic stem cells. This function is mediated through the core en-
hancer DNA sequence present in the promoters and enhancers
The core binding factors are a small family of heterodimeric tran- of a large number of hematopoietic specific genes. AML1 binds
scription factors that control critical cell fate decisions in a num- this sequence through its central runt homology domain (RHD),
ber of different cell lineages (Downing, 1999; Speck et al., 1999; and its DNA binding affinity is increased by heterodimerizing
Downing et al., 2000). This family is comprised of one of three through this domain with CBF (Wang et al., 1993; Ogawa et al.,
different DNA binding subunits (Runx1–3) with homology to the 1993).
Drosophila pair rule gene runt, and a single common  subunit A surprising finding that has emerged from the study of
(CBF). The heterodimeric complex composed of Runx1 (also AML1/CBF has been that the genes encoding this transcription
called AML1, CBFA2, and PEBP2B; referred to as AML1 for the factor complex are some of the most frequent targets of genetic
remainder of this article) and CBF is essential for the formation alterations in human acute leukemias (Downing, 1999; Speck et
of the entire definitive hematopoietic system (Okuda et al., 1996; al., 1999; Downing et al., 2000; Friedman, 1999). This complex is
altered by chromosomal rearrangements in up to 30% of humanWang et al., 1996a, 1996b; Sasaki et al., 1996). Loss of the genes
encoding either subunit results in an embryonic lethal phenotype acute leukemias, with the AML1 subunit being targeted by the
t(8;21), t(3;21), t(16;21), and a variety of other rarer translocationsat the midpoint of embryologic development from a complete
absence of definitive hematopoietic stem cells. Thus, AML1/ in acute and chronic myeloid leukemias, and by the t(12;21) in
pediatric acute lymphoblastic leukemia. Similarly, the CBF sub-CBF appears to function as a master regulatory switch that es-
tablishes a transcriptional cascade that controls critical cell fate unit is altered by the inv(16) and t(16;16), found primarily in the
acute myeloid leukemia (AML) subtype, M4Eo (Liu et al., 1993).decisions necessary for the development of definitive hemato-
S I G N I F I C A N C E
One of the more prevalent subtypes of human acute myeloid leukemia is the so-called “core binding factor leukemias,” which are
characterized by alterations of the genes encoding the AML1/CBF transcription factor complex. Here we report a murine model of this
leukemia subtype. Key to the developmentof this model was the use of a conditional AML1-ETO knockin allele that mimicked the human
t(8;21) translocation. This murine model will serve as a powerful tool to identify the spectrum of mutations that cooperate with AML1-ETO
in leukemogenesis, and to assess novel therapies that target either AML1-ETO or components of its downstream signaling pathway. In
addition, the experimental strategy employed here should have broad applicability in the generation of other animal models of human
malignancies. Through the use of a conditional transcriptional stop cassette, the expression of dominantly acting oncogenes or tumor
suppressors can be regulated in both a temporal and lineage-specific manner.
CANCER CELL : FEBRUARY 2002 · VOL. 1 · COPYRIGHT  2002 CELL PRESS 63
A R T I C L E
Figure 1. Generation of mice with a conditional AML1-ETO knockin allele
A: Schematic of AML1 cDNA, partial murine AML1 genomic locus, replacement targeting vector, the targeted AML1-ETO-stop knockin allele generated by
homologous integration of the vector, and the activated allele with a deleted stop cassette following Cre-mediated recombination. AML1 exons 3 and 4 are
indicated by solid boxes. The stop cassette bracketed by loxP recombination sequences, partial human AML1-ETO cDNA, polyadenylation signal (poly A),
positive selection neomycin resistance cassette (neor), negative selection diptheria toxin-A cassette (DT-A), and hybridization probe (5-probe) are shown. B:
Schematic showing the approach used to test for Cre-mediated activation of the AML1-ETO-stop allele. C: Western blot analysis of AML1-ETO. Cells analyzed
include fetal liver cells from AML1-ETO heterozygous embryos (lane 1), bone marrow cells from wild-type mice (lane 2), and bone marrow cells from AML1-ETO-
stop mice either infected with an empty retrovirus (lane 3) or with the MSCV-Cre-IRES-GFP retrovirus (lane 4).
Each of these chromosomal rearrangements results in the forma- 1997) or dysplastic multilineage hematopoietic progenitors that
had an abnormally high self-renewal capacity in vitro (Okuda ettion of AML1 or CBF fusion proteins that retain domains neces-
sary for either DNA binding and/or heterodimerization with the al., 1998). Thus, AML1-ETO not only neutralized the normal bio-
logic activity of AML1, butalso directly induced aberrant hemato-wild-type partner protein. Functionally, these fusion proteins ap-
pear to act in a dominant negative fashion to inhibit the normal poietic cell proliferation. Importantly, however, AML1-ETO-
expressing cells failed to expand within the developing embryos,transcriptional activity of AML1/CBF (Downing, 1999; Speck et
al., 1999;Downingetal., 2000). Inaddition,pointmutationswithin or to induce leukemia when transplanted intosyngeneic or immu-
nocompromised recipients (Yergeau et al., 1997; Okuda et al.,the RHD of AML1 have been identified as the underlying cause
of a familial platelet disorder with a predisposition to AML, and 1998). This latter result suggests that AML1-ETO alone is not suf-
ficient to induce leukemia.as somatic events in rare cases of de novo AML and myelodys-
plastic syndrome (Song et al., 1999; Osato et al., 2000; Preud- The embryonic lethal phenotype that results from the expres-
sion of AML1-ETO during murine development precludes the usehomme et al., 2000; Imai et al., 2000).
To investigate the mechanistic role of the t(8;21)-encoded of this system to explore the mechanism through which AML1-
ETO contributes to leukemogenesis. To circumvent this hurdle,AML1-ETO fusion protein in leukemogenesis, we and others
used gene targeting to create mice with an AML1-ETO knockin we have now generated a murine line with a conditional AML1-
ETOknockinallele, inwhichastrongtranscriptionalstopcassetteallele that mimics the t(8;21) (Yergeau et al., 1997; Okuda et al.,
1998). Embryos heterozygous for AML1-ETO, like AML1-defi- bracketed by loxP sites was placed 5 to the AML1-ETO fusion
site. While this allele is transcriptionally silent in its intact state, itcientmice,diedaroundE13.5 fromacompleteabsenceofnormal
fetal liver-derived definitive hematopoiesis. However, in contrast can be activated following birth through Cre-mediated deletion of
the transcriptional stop cassette. Activation results in AML1-ETOto AML1-deficient embryos, fetal livers from AML1-ETO/ em-
bryos contained either abnormal monocytes (Yergeau et al., expression driven off of the endogenous AML1 regulatory se-
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quences, thus closely mimicking the molecular consequences of tween murine AML1 exon 3 and the fused murine exon 4-human
AML1-ETO sequences (data not shown). Taken together, thesethe t(8;21) translocation. Using these mice, we now demonstrate
that expression of AML1-ETO in adult mice does not block the data suggest that the conditional AML1-ETO allele can be effi-
ciently activated through Cre-mediated deletion of the transcrip-ability of hematopoietic cells to differentiate, but instead induces
an enhanced in vitro replating efficiency of myeloid progenitors. tional stop cassette.
Moreover, AML1-ETO alone was shown to be insufficient to in-
duce leukemia, but following the acquisition of cooperating mu- In vivo activation of the conditional AML1-ETO
allele alters the growth propertiestations, efficiently led to the development of an acute myeloid
neoplasm that mimicked many of the features of human AML1- of hematopoietic progenitors
To activate the conditional AML1-ETO allele in vivo, we crossedETO-expressing leukemia. These results dramatically demon-
strate the value of using a conditional knockin strategy to create the AML1-ETO-stop/ mice with a murine line transgenic for a
Cre recombinase gene driven off of the interferon (IFN)-/a mouse model of human cancer induced by an oncogenic fusion
protein. -inducible Mx1 promoter (Kuhn et al., 1995). This promoter can
beactivated invivo by treatmentofmicewitheither IFN-/or the
synthetic double-stranded RNA, polyinosinic-polycytidylic acidResults
(pI-pC), which activates the expression of endogenous IFN.
Treatment with either agent results in the expression of Cre inGeneration of a conditional AML1-ETO knockin allele
To circumvent the embryonic lethality that results from expres- cells that contain the receptor for IFN-/. Although this results
in deletion of the transcriptional stop cassette in a broad rangesion of AML1-ETO, we generated mice with a conditional AML1-
ETO knockin allele. This allele was constructed by fusing human of hematopoietic and nonhematopoietic cells (Kuhn et al., 1995),
expression of the activated AML1-ETO-stop allele is restricted toAML1-ETO sequences in frame to murine AML1 exon 4 and in-
serting a loxP bracketed transcriptional stop cassette (Lakso et cells that normally express AML1, thus providing lineage speci-
ficity.al., 1992) 5 to the AML1-ETO fusion in intron 3 (Figure 1A). This
cassette results in the efficient termination of transcripts within As shown in Figure 2, BM cells from pI-pC treated single
transgenic AML1-ETO-stop/, and Mx1-Cre/ mice, and fromits sequence, thus preventing the generation of full-length AML1-
ETO transcripts. While this allele is transcriptionally silent in the untreated double transgenic AML1-ETO-stop/ Mx1-Cre/
mice showed no significant evidence of deletion of the stop cas-germline, it can be activated following birth through Cre-medi-
ated deletion of the transcriptional stop cassette. Activation re- sette (Figure 2A), and failed to express the AML1-ETO chimeric
protein (Figure 2B). By contrast, treatment of AML1-ETO-stop/sults in AML1-ETO expression driven off of the endogenous
AML1 regulatory sequences, and thus allows the activated allele Mx1-Cre/ double transgenic mice with three intraperitoneal in-
jections of pI-pC over a six-day period resulted in the rapid dele-to retain the temporal, lineage specific, and quantitative tran-
scriptional control afforded by AML1 transcriptional regulatory tion of the transcriptional stop cassette and the efficient expres-
sion of AML1-ETO (Figures 2A and 2B).sequences. Therefore, this approach should provide a significant
advantage over the alternative approach of expressing the To assess the in vivo efficiency of Cre-mediated activation of
the conditional allele, we measured the level of deletion of theAML1-ETO oncoprotein from a transgene containing a heterolo-
gous lineage-specific promoter. Targeted ES cells (AML1-ETO- stop cassette by Southern blot analysis in BM cells as a function
of time following pI-pC treatment. One week after the last pI-pCstop/) with normal ploidy were obtained and used to achieve
germline transmission of the allele. injection, 35% of BM cells had undergone deletion (Figure 2C).
By two weeks, this percentage increased to greater than 85%In contrast to the embryonic lethal phenotype seen with mice
heterozygous for AML1-ETO, AML1-ETO-stop/ heterozygous and was sustained at this level throughout the life of the animal.
Moreover, AML1-ETO expression was easily detected by West-mice were viable and were born at a normal Mendelian ratio.
Moreover,RT-PCRanalysisdemonstratedtheabsenceofappro- ern blot analysis and its level of expression directly correlated to
the percentage of cells containing a deleted allele (Figure 2B andpriately spliced AML1-ETO transcripts from AML1 exon 3
through ETO sequences, and Western blot analysis failed to de- data not shown). Since Cre expression is maintained for at most
2–3 days following pI-pC injections, the observed increase intect any AML1-ETO fusion proteins using antibodies specific for
the N terminus of AML1 or the C terminus of ETO (data not shown AML1-ETO-expressing BM cells over time suggests that these
cells may have an in vivo selective growth advantage. The persis-and Figure 1C). Thus, the strategy used effectively blocked ex-
pression of the AML1-ETO allele during murine development. tent expression of AML1-ETO throughout the life of the mice sug-
gests that Cre-mediated deletion of the stop cassette may beTo test our ability to activate the AML1-ETO-stop allele, we
harvested bone marrow (BM) cells from 5-flourouracil treated occurring in long-term repopulating hematopoietic progenitors
(see below).adult AML1-ETO-stop/ mice and infected these cells in vitro
with an MSCV-based retrovirus (Persons et al., 1997) that ex- Interestingly, following pI-pC injection, 90% of BM and 49%
of spleen cells contained an AML1-ETO-stop allele with a deletedpressed both the Cre recombinase and the green fluorescence
protein (GFP) (Figure 1B). Infected hematopoietic cells were flow stop cassette, whereas thymocytes contained only background
levels of this activated allele (Figure 2D). Moreover, high levels ofsorted for GFP positivity and analyzed by Western blot analysis
for evidence of expression of AML1-ETO. As expected, infection AML1-ETOmRNAweredetected in totalBMcellsandflowsorted
splenic B cells, whereas only trace levels of transcript were de-with the Cre-expressing retrovirus resulted in expression of the
appropriately sized AML1-ETO chimeric protein (Figure 1C). tected in isolated T cells, despite the fact that T cells express a
high level of wild-type AML1 (data not shown). Since previousSouthern blot analysis demonstrated that the floxed stop cas-
sette had been deleted, and sequence analysis of transcripts ex- studies have demonstrated that the Mx1 promoter results in the
expression of a functional Cre protein in developing and maturepressed from this allele demonstrated appropriate splicing be-
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Figure 2. Cre-mediated recombination leads to efficient in vivo activation of the conditional AML1-ETO knockin allele
A: Southern blot analysis of bone marrow cells from single transgenic AML1-ETO-stop/, Mx1-Cre/, or double transgenic AML1-ETO-stop/Mx1-Cre/ mice
either untreated or injected with pI-pC to induce Cre-expression. Deletion of the stop cassette (9.0 kb deleted allele) is only seen in cells from the double
transgenic mice following pI-pC injection. B: Western blot analysis of AML1-ETO. C: Southern blot showing a time course in weeks (w) for Cre-mediated deletion
following pI-pC injection. The percentage of AML1-ETO-stop (knockin allele) and deleted allele are indicated. D: Southern blot showing the percentage of
activated (deleted) allele in different organs from induced and uninduced double transgenic AML1-ETO-stop/Mx1-Cre/ mice.
T cells (Kuhn et al., 1995), these data raise the possibility that of the AML1-ETO chimeric transcript was detected by RT-PCR
analysis in 25/26 individual multipotential mixed (myeloid, mono-expression of AML1-ETO may selectively compromise T cells’
survival. cytic, erythroid, and megakaryocytic) colonies generated from
BM cells obtained from double transgenic mice 4–12 weeks fol-Previousstudieshavedemonstrated thatexpressionofAML-
ETO can induce an increase in the self-renewal capacity of hema- lowing pI-pC treatment. In addition, AML1-ETO expression was
detected in 22/23 multipotential day 12 spleen colony-formingtopoieticprogenitors (Okudaetal.,1998).Todetermine if the level
of AML1-ETO expressed from this in vivo activated allele was units (CFU-S12) from pI-pC treated double transgenic mice (data
not shown). Moreover, when BM cells from pI-pC treated doublesufficient to induce this phenotype, BM cells were plated in meth-
ylcellulose-containing media in the presence of cytokines, and transgenic mice were transplanted into lethally irradiated recipi-
ents, AML1-ETO-expressing cells were detected in both myeloidcolonies were counted following seven days of growth. The pop-
ulation of colonies were then pooled, washed, and 1  104 cells and B cells of the recipients 6 months following transplantation
(data not shown). Importantly, no evidence of leukemia devel-replated in methylcellulose,and this processwas repeated reiter-
atively every seven days. As shown in Figure 3A, following activa- oped in the mice transplanted with these AML1-ETO-expressing
BM cells.These dataare consistentwith Cre-mediatedactivationtion with the Mx1-Cre transgene, the AML1-ETO-expressing
cells were able to form myeloid colonies long after non-AML1- of the conditional AML1-ETO allele occurring in multi-lineage he-
matopoietic progenitors, and possibly long-term repopulatingETO-expressing cells stopped growing. Importantly, the AML1-
ETO-expressing cells were absolutely dependent on the pres- hematopoietic stem cells.
To quantify the effect of AML1-ETO on the replating capacityence of hematopoietic growth factors for both proliferation and
survival (data not shown). The majority of the colonies detected of hematopoietic progenitors on a clonal basis, individual mixed
colonieswereharvested fromBMculturesderivedfromwild-typein the methylcellulose cultures were granulocyte-macrophage,
with only rare erythroid and mixed lineage colonies identified in mice (10 colonies), pI-pC treated double transgenic AML1-ETO-
stop/Mx1-Cre/ mice (10 colonies), and AML1-ETO-express-late passage cultures. In addition, terminally differentiated my-
eloid cells were present in the cultures, suggesting that AML1- ing fetal liver cultures obtained from mice containing an tradi-
tionalAML1-ETOknock-inallele (20colonies,Okudaetal., 1998).ETO alters the self-renewal capacity of cells without significantly
affecting their ability to differentiate. As shown in Figure 3B, individual mixed colonies from wild-type
cells rapidly lost their in vitro replating capacity, with no coloniesThe identification of mixed lineage colonies in the long-term
cultures suggests that Cre-mediated recombination is occurring observed following the third replating. By contrast, individual
AML1-ETO-expressing BM and fetal liver mixed colonies gavenot only in committed myeloid cells, but also in some immature
multi-lineage progenitor. In support of this notion, the expression rise to long-term colony forming cells at very high efficiency
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AML1-ETO expression appeared to induce a slight increase in
the number of granulocyte-monocyte (GM), mixed, and total col-
onies (Table 1). Similarly, a slight increase was found in the num-
ber of CFU-S12 in BM cells from AML1-ETO-expressing mice as
compared to uninduced double transgenic AML1-ETO-stop/
Mx1-Cre/mice (22.03.8 colonies/1105 cells versus 15.6
4.7 colonies/1 105 cells, respectively). These data dramatically
demonstrate that expression of AML1-ETO fails to significantly
impair the differentiation of hematopoietic progenitors.
Importantly, although AML1-ETO was expressed in a high
percentage of hematopoietic cells including immature multipo-
tential progenitors, no leukemia or other hematopoietic neo-
plasms developed during the first 11 months of life in a cohort of
20 AML1-ETO-expressing mice. However, by one year of age,
two mice in this group developed hematopoietic neoplasms: one
with a T cell lymphoma, and one with an undifferentiated lym-
phoma (Group 3, Table 2). Each tumor expressed the AML1-ETO
protein (data notshown). Taken together, thesedata suggest that
Figure 3. Expression of AML1-ETO increases the in vitro replating efficiency of expression of AML1-ETO in adult hematopoietic cells results in
adult bone marrow cells
a slight increase in the number of multipotential progenitors, but
A: BM cells were plated in methylcellulose-containing media in the presence does not significantly alter the in vivo growth of these cells or their
of cytokines and colonies were counted following 1–2 weeks of growth. The
ability to terminally differentiate. Moreover, expression of AML1-total population of colonies was then pooled, washed, and 1  104 cells re-
ETO is insufficient by itself to induce leukemia.plated in methylcellulose, and this process was repeated reiteratively every
seven days. The number of colonies/1  104 cells as a function of the total
days in culture is shown. B: Individual mixed colonies were harvested from Secondary mutations can cooperate with AML1-ETO
BM cultures derived from wild-type mice (10 colonies), pI-pC treated double
to induce myeloid leukemiatransgenic AML1-ETO-stop/Mx1-Cre/mice (10 colonies), and from AML1-
The rare occurrence of hematopoietic neoplasms after a long la-ETO-expressing fetal liver cultures obtained from mice containing an tradi-
tional AML1-ETO knockin allele (20 colonies). Colonies obtained following the tency in the AML1-ETO-expressing mice suggests that addi-
initial growth of the individual mixed colonies were then serially passed in tional genetic event(s) are required to induce the full leukemic
culture as outlinedabove. The number of original colonies that were capable transformation of hematopoietic progenitors. To directly test this
of generating new colonies during each in vitro passage is indicated.
hypothesis, 5- to 10-week-old AML1-ETO-stop/ Mx1-Cre/
micewere treatedwithpI-pC to induceexpression ofAML1-ETO,
and after two weeks these mice were treated with a single muta-
genic dose of the DNA alkylating agent, N-ethyl-N-nitrosourea(50%). Moreover, cytokine-dependent myelomonocytic cell
(ENU, 50 mg/kg). Although this dose of ENU efficiently induceslines could be readily established from these cultures (data not
single base mutations (Breuer et al., 1991), only 2 hematopoieticshown). Although these cultures were initiated from individual
neoplasms,a thymic-derivedTcell lymphoblastic lymphomaandmixed lineage colonies, the majority of colonies in each replated
a histiocytic lymphoma, developed in the ENU treated controlcultureweremyeloid/monocytic innature,withonly rareerythroid
groups that lacked AML1-ETO expression (Table 2). By contrast,and mixed colonies observed. No change in the type of colonies
47% (17/36) of the AML1-ETO-expressing mice developed he-was observed following the initial replating, and no blast colonies
matopoietic neoplasms 2–10 months after treatment (Table 2).were detected, suggesting that the serial growth was derived
Two distinct types of malignancies were identified: granulocyticfrom more committed progenitors. Thus, the in vivo activation
sarcoma/acute myeloid leukemia that was highly reminiscent ofof the Mx1-Cre transgene results in an increase in the replating
aspects of the disease seen in patients with t(8;21)-containingcapacity of myeloid progenitors such that a high percentage of
AML (11/36, 31%), and thymic derived T cell lymphoblastic lym-these cells are able to bypass culture-induced senescence and
phomas (6/36, 17%). Of the latter tumors, 4/5 analyzed casesestablish permanent cell lines. Injection of the AML1-ETO BM-
failed to express AML1-ETO by Western blot analysis, sug-derived cell lines into SCID or sublethally irradiated syngeneic
gesting that these are likely to represent ENU-induced thymicmice failed to lead to the development of leukemia (data not
lymphomas that may not be a direct result of AML1-ETO expres-shown).
sion. The T cell tumors will be discussed below.
The granulocytic sarcomas consisted of solid masses of pro-Expression of AML1-ETO in vivo induces minimal
liferating myeloblasts arising within the retropertinuem, soft tis-hematopoietic abnormalities in adult mice
sue, or bones of the sternum, cranium, or extremities and ex-Although AML1-ETO was expressed in a high percentage of he-
tending into the adjacent soft tissue (Figures 4A–4H). Thesematopoietic cells and altered their in vitro growth characteristics,
tumors were composed of sheets of myeloblasts showing vari-only minimal alterations were observed in vivo in the hematopoi-
able expression of myeloperoxidase, admixed with a few matur-etic systems of these mice. No significant abnormalities were
ing myeloid cells. The tumor cells were negative for T cell markersseen in their hematocrits, nucleated blood cell counts, white
andexpressedvariable levelsofCD34,c-Kit,Sca-1,Mac-1,Gr-1,blood cell or red cell differentiation, or platelet counts (negative
TER119 and B220 (data not shown). Although distinct tumordata not shown). Moreover, no histological abnormalities were
masses were evident in mice at presentation, death was rapidobserved in any of the hematopoietic organs. However, when
the number of hematopoietic colony forming cells was assessed, and necropsy revealed widespread dissemination of the blasts
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Table 1. Bone marrow hematopoietic progenitors
Genotype
AML1-ETO-stop Mx1-Cre pl-pC GM G M CFU-E BFU-E Meg Mixed Total
KI/ /  62.7  3.1a 26.3  1.5 3.0  1.0 0.3  0.6 6.0  2.6 1.3  0.6 15.3  2.1 115.0  6.2
KI/ /  49.3  0.6 21.3  6.1 4.0  1.7 0.3  0.6 2.7  0.6 0.3  0.6 11.3  1.5 89.3  5.5
KI/ /  38.7  5.0 28.0  10.5 4.7  1.5 1.0  0.0 5.0  2.6 0 9.7  1.5 87.0  16.5
1  104 viable cells were plated in triplicate into 35 mm methylcellulose cultures. Numbers represent means plus or minus standard deviations.
a P  0.05 compared with each of the other groups. GM, granulocyte-macrophage colonies; G, granulocyte colonies; M, macrophage colonies; CFU-E,
colony-forming units-erythroid; BFU-E, burst-forming units-erythroid; Meg, megakaryocyte colonies; Mixed, mixed hematopoietic colonies.
with clusters of malignant cells present within the spleen, liver, ever, recipient mice had widespread dissemination of the leuke-
mic myeloblasts with involvement of BM, spleen, lymph node,kidney, and lymph nodes (Figures 4F–4H, and data not shown).
In some mice, an increase in myeloblasts was also noted within and liver. The granulocytic sarcomas in the recipient mice were
histologically identical to those seen in the primary animals, withthe BM (Figure 4E). Although the peripheral blood counts of my-
eloid tumor-bearing mice showed marked variability, four mice the majority of cells consisting of myeloblasts admixed with rare
maturing granulocytes. Cells isolated from the tumors of trans-had anemia coupled with markedly increased WBC counts (be-
tween 15,000–50,000 cells/	l), with easily identified circulating planted mice readily grew as immature myeloid cell lines in liquid
culture.leukemic blasts.
Cells isolated from the granulocytic sarcomas expressed
AML1-ETO (8/8 tumors analyzed, representative results shown Altered growth factor signaling pathways cooperate
with AML1-ETO to induce leukemiain Figure 5C) grew efficiently in vitro in liquid cultures and formed
colonies in methylcellulose-containing media that were com- Pinpointing the critical ENU-induced mutation(s) that cooperate
with AML1-ETO to induce leukemia will be difficult since multipleposedofblastsadmixedwith rarematuringmyeloidanderythroid
cells. These cells readily established immortalized AML1-ETO- mutations are likely to have resulted from the dose of ENU used.
Nevertheless, since the transformation of murine cells frequentlyexpressing immature myeloid cell lines that showed variable ex-
pression of CD34, c-Kit, Sca-1, TER119, Mac-1, and Gr-1, and involves alterations of the p19Arf/Mdm2/p53 or p16INK4A/pRb cell
cycle checkpoint responses, we examined several componentscontinued to give rise to rare mature myeloid and erythroid cells
inculture (Figures5Aand5B).TheseAML1-ETO-expressing lines of these pathways to see if they had been altered either directly
by AML1-ETO or by ENU mutagenesis. No mutations were de-contained a diploid content of DNA when analyzed by flow cy-
tometry after propidium iodide staining and lacked evidence of tected in theDNAbindingdomainofp53bydirectsequenceanal-
ysis in 8/8 AML1-ETO-expressing myeloid tumors. Moreover, byrecurrent chromosomal rearrangements as assessed by routine
cytogenetic analysis and spectral karyotyping (data not shown Western blot analysis, the p53 transcription factor was rapidly
induced following X-ray irradiation, and resulted in the inductionand Figure 5D). Importantly, one tumor was found to have a tri-
somy of chromosome 17 in all analyzed metaphases, suggesting of the p21 cyclin-dependent kinase inhibitor and apoptosis
(Figure 6A and data not shown). These results suggest that thea clonal neoplasm.
The granulocytic sarcomas were readily transplantable into AML1-ETO-expressing cells maintain an intact p53-dependent
checkpoint. Expression of both p19Arf and p16INK4A is known to berecipient mice. Cells from tumors were injected subcutaneously
into SCID mice, and granulocytic sarcomas developed at the site progressively induced following serial passage of wild-type BM
cells in culture and is frequently lost in immortal BM-derived cellof injection ineach recipient.Similarly, cellswere injected intrave-
nously into syngeneic recipients and AML1-ETO-expressing my- lines (Sherr, 2001; Randle et al., 2001). Surprisingly, p19Arf and
p16INK4A expression was maintained in 8/8 AML1-ETO-express-eloblastic proliferations were detected within 3–14 weeks. Inter-
estingly, in some of the mice injected intravenously, solid masses ing myeloid tumors (Figure 6B), suggesting that the expression
of these cell cycle regulators isunlikely tobe significantlyeffectedof proliferating myeloblasts developed near the site of injection.
For example, injection into the retro-orbital sinus resulted in large by AML1-ETO expressed from the conditional allele. Despite the
persistentexpressionof thesecellcycle inhibitors, the tumorcellsorbital tumors, whereas injection into the tail vein typically re-
sulted in tumor masses at the base of the tail. At necropsy, how- continue to proliferate both in vitro and in vivo.
Table 2. Hematopoietic neoplasms in AML1-ETO-stop mice
Genotype
No. of evaluable Granulocytic T cell
Group AML1-ETO-stop Mx1-Cre pl-pC ENU mice sarcoma lymphoma other tumor
1 KI/ /   36 11 6 0
2 KI/ /   13 0 0 0
3 KI/ /   15 0 1 1a
4 KI/ /   13 0 0 0
5 KI/ /   15 0 1 1b
a Undifferentiated lymphoma. b Histiocytic lymphoma.
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Figure 4. Morphology and immunohistochemi-
cal featuresofAML1-ETO-expressinggranulocytic
sarcomas
Low (A) and high power (B) view of hematoxylin
and eosin stained sections of a granulocytic sar-
coma that arose in the cranium. Myeloperoxi-
dasepositive tumorcellswereeasily detected(C)
and the majority of the cells had immature blast
like morphology; however, scattered mature my-
eloid cells were seen (D). At death the mice
showed widespread dissemination of tumors cells
with involvement of bone marrow (E), spleen (F),
liver (G), and kidney (H). The insert in (G) is stained
with myeloperoxidase.
An important observation that might provide insight into the show a marked increase in the phosphorylated form of the retino-
blastoma protein (Rb), consistent with its functional inactivationnature of the cooperating mutations was the marked difference
in growth factor requirements of the AML1-ETO-expressing non- (Figure 6C). No evidence of CDK4 gene amplification was seen,
suggesting that its increased expression is transcriptional ortumorigenic cell lines versus those derived from the AML1-ETO-
expressing myeloid tumors. Specifically, all of the immortal my- posttranscriptional in nature (data not shown).
The cytokine-independent growth of the tumors does not ap-eloid cell lines generated from AML1-ETO expressing BM were
absolutely dependent on cytokines for both their growth and sur- pear to be the result of an autocrine production of growth factors,
since conditioned media from cultures of tumor cells failed tovival,whereasthecell linesderivedfromtheAML1-ETO-express-
ing myeloid neoplasms grew efficiently in media that contained support the growth of AML1-ETO immortal nontumor cell lines
(data not shown). In addition, no mutations were detected infetal bovine serum and insulin, but lacked other exogenous cyto-
kines (data not shown). This cytokine independent growth of the N-ras, K-ras, or H-ras by direct sequence analysis in 8/8 tumors.
Thus, although cytokine signaling pathways are clearly alteredtumor-derived lines suggest that the mutations that cooperate
with AML1-ETO to induce leukemia might involve critical alter- in the AML1-ETO tumors, the nature of the specific mutations
remains to be defined.ations in growth factor signaling pathways that allow cells to pro-
liferate in the face of persistent p19Arf and p16INK4A expression. Lastly, since biallelic inactivating mutations of AML1 have
been identified in rare sporadic cases of human acute myeloidConsistent with this hypothesis, the AML1-ETO-expressing my-
eloid tumors showedan increase in the levelofexpression ofboth leukemia with minimal differentiation (Song et al., 1999; Osato et
al., 2000; Preudhomme et al., 2000; Imai et al., 2000), we alsoCDK4 and cyclin D2 as compared to the levels observed in the
AML1-ETO nontumor cell lines (Figure 6C). Moreover, the tumors sequenced the wild-type AML1 allele in the AML1-ETO-express-
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Figure 5. AML1-ETO-expressingtumorderivedcell
lines
A and B: Cells from granulocytic sarcomas were
cultured in the absence of cytokines for 4 weeks
prior to morphologic analysis. Cytocentrifuge
preparations were stained with Wright-Giemsa.
Arrows indicate mature myeloid and erythroid
cells. C: Western blot analysis for AML1-ETO. Sam-
ples includefetal livercells fromAML1-ETOhetero-
zygous embryos (AML1-ETO-KI), BM cell from a
wild-type mouse (wild-type), primary tumor tissue
from a granulocytic sarcoma (GS-1), and cul-
tured cells from a granulocytic sarcoma (GS-2).
D: Spectral karyotype of cells from granulocytic
sarcomas.
ing tumor lines to determine if ENU mutatgenesis might have tar- chemicalmutagenENUinducedamalignantproliferationofmye-
loblasts in 31% of animals. Although these neoplasms presentedgeted this allele. No mutations were detected in the DNA binding
runt homology domain of AML1 in 8/8 tumors. The complete ab- initially as granulocytic sarcomas similar to those seen in some
human patients with t(8;21)-containing AML, the disease rapidlysence of mutation in five different genes in each of the analyzed
tumors suggests that the expression of AML1-ETO is unlikely to disseminated throughout the animals. In addition, the tumors
were transplantable intoprimary recipientsandformed immortal-be inducing global genetic instability. Further supporting this in-
terpretation is the fact that both the AML1-ETO leukemias and ized factor-independent cell lines confirming their malignant na-
ture. Thus, this murine model provides direct experimental evi-nontumor cell lines are diploid and lack structural chromosomal
abnormalities. dence that contrary to current models, expression of AML1-ETO
in adult myeloid progenitors does not block differentiation, but
instead contributes to their immortalization. Moreover, AML-Discussion
ETO-induced leukemia is a multistep process, in which second-
ary genetic alterations cooperate with AML1-ETO to alter differ-By using a knockin strategy that couples a lox-P bracketed tran-
entiation and induce full transformation.scriptional stop cassette with an inducible Cre transgene, we
The mechanism through which AML1-ETO increases thegeneratedamouse inwhich lineagespecificexpressionofAML1-
self-renewal capacity of hematopoietic progenitors remains toETO can be temporally controlled. This strategy allows us to by-
be defined. Although an increase in replating efficiency was ob-pass the embryonic lethal phenotype that results from the ex-
served, only half of the individual multi-lineage progenitors werepression of AML1-ETO and to directly define the contribution of
able to give rise to long-term colony growth and immortal cyto-this fusion protein to the development of leukemia in the adult
kine-dependent cell lines. These data suggest that AML1-ETOmouse. Following AML1-ETO expression, a slight increase was
may not directly induce hematopoietic cells to bypass culture-noted in the number of multipotential progenitors; however, the
induced replicative senescence, but instead may result in en-in vivo growth of these cells appeared normal, with no significant
hanced or prolonged growth of the cells in vitro, from which sub-alterations in the numbers of hematopoietic cells or their extent
clones can emerge that have escaped senescence.of differentiation. Despite showing minimal in vivo growth abnor-
The inability of AML1-ETO expressed from the endogenousmalities, these AML1-ETO-expressing BM cells showed a mark-
edly enhanced in vitro replating efficiency, and readily formed AML1 transcriptional regulatory sequences to significantly alter
differentiation of hematopoietic progenitors is in stark contrast toimmortal cytokine-dependent myeloid cell lines. Thus, although
expression of AML1-ETO directly alters the growth characteris- results obtained using a variety of cell lines (Kohzaki et al., 1999;
Burel et al., 2001; Sykes and Kamps, 2001). In most of the lattertics of hematopoietic progenitors, the resultant cells remain re-
sponsive to normal in vivo homeostatic controls. Importantly, experiments, AML1-ETO was constitutively expressed from het-
erologous promoters, including retroviral LTRs. These situationsonly a rare AML1-ETO-expressing mouse spontaneously devel-
oped a hematopoietic neoplasm after a long latency (12 months), fail to mimic the normal marked downregulation of AML1 expres-
sion, and presumably AML1-ETO expression, that occurs duringdemonstrating that expression of AML1-ETO alone is not suffi-
cient to induce the transformationof hematopoietic cells.By con- normal myeloid differentiation. Moreover, the level of AML1-ETO
expressed from our conditional allele was 5- to 10-fold less thantrast, treatment of the AML1-ETO-expressing mice with the
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transform to overt leukemia. Similar observations have recently
been made in other models of core binding factor leukemias. In
experiments using chimeric mice containing a knockin allele that
mimics the inv(16)-encoded CBFMYH11, acute myelomono-
cytic leukemias develop after ENU-induced mutagenesis (Cas-
tillaetal., 1999).Similarly, inmicecontaininganAML1-ETO trans-
gene driven off of the myeloid specific MRP8 promoter, a myeloid
diseasedeveloped followingENUmutagenesis;however, the lat-
ter cells were not shown to be transplantable, nor were their in
vitro growth potential assessed (Yuan et al., 2001). Lastly, in a
recent mouse model that induced Cre/LoxP mediated interchro-
mosomal recombination between AML1 and ETO, the efficiency
of the recombination was too low to allow a direct assessment of
the leukemic potential of AML1-ETO (Buchholz et al., 2000).
Several features of the acute myeloid disease/leukemia that
develop in these mice accurately mimic those seen in human
t(8;21)-containing leukemia. One of the perplexing findings in the
human disease has been the tendency for the leukemic cells to
frequently grow as solid tumors (Abe et al., 1986; Hagihara et al.,
1991; Tallman et al., 1993). Although granulocytic sarcomas are
seen in other types of leukemia, in acute leukemias they are most
prevalent in the t(8;21) AMLs, being observed either at presenta-
tion or during the course of the disease in up to 22% of the pa-
tients (Abe et al., 1986; Hagihara et al., 1991; Tallman et al., 1993;
Neiman et al., 1981; van Veen et al., 1991; Bitter et al., 1987). The
predominant formation of granulocytic sarcomas in the murine
model suggests that expression of AML1-ETO must directly re-
sult in the development of leukemic cells that have cell surface
features that foster growth as adhesive masses. Although the
reason for this type of growth remains unknown, genome-based
Figure 6. Intact p53 checkpoint, persistent p19Arf and p16INK4a expression, and gene expression analysis of the neoplastic cells should provide
functional pRb inactivation in AML1-ETO-expressing tumors
critical insights into the expression of adhesion or homing mole-
A:AML1-ETO-expressingtumorcellswere growasgrowthfactor independent
cules that contribute to this pattern of growth. A second featurecell lines and irradiated at dose of 5.6 G at 760 rads/min. Following irradiation,
of the murine disease that resembles that seen in humans is thethe cells were then grown for the indicated times, lysed, and analyzed by
Western blot for expression of p53 and p21. Results from two representative persistent ability of the leukemic blasts to undergo some terminal
cell lines are shown. B: AML1-ETO-expressing tumors were analyzed by West- differentiation. Patients with t(8;21) leukemias frequently have
ern blot for expression of p19Arf and p16INK4a C: AML1-ETO-expressing immortal mature myeloid cells including neutrophils that are part of the
bone marrow cells (A-E Im. BM) and tumors were analyzed by Western blot
leukemic clone (Berger et al., 1982; Swirsky et al., 1984).for expression of CDK4, Cyclin D2, and phosphorylated pRb.
An important observation from our studies is that the nonleu-
kemic AML1-ETO-expressing cell lines were cytokine-depen-
dent, whereas cell lines derived from AML1-ETO-expressing leu-
kemias were factor-independent. These data strongly suggestthe levels achieved using a retrovirus (J.D. and N.L., unpublished
that one signaling pathway that may collaborate with AML1-ETOdata). These differences are likely to have profound biologic con-
is cytokine-mediated proliferation or survival. Support for this hy-sequences and highlight the need to closely mimic the situation
pothesis comes from the recent identification of a case of TEL-seen in the human disease so that correct biologic insights can
PDGFR-expressing chronic myelomonocytic leukemia (CMML)be made.
that underwent blastic transformation to AML following acquisi-A clear result that emerges from our data is that the expres-
tion of the t(8;21), and a second case of a patient with BCR-ABL-sion of AML1-ETO by itself is not sufficient to induce leukemia.
expressing CML, who during accelerated phase was found toHowever, by inducing cooperating mutations with ENU, we were
have acquired a t(8;21) (Kojima et al., 2000). In both examples,able to efficiently develop acute myeloid leukemia/granulocytic
coexpression of AML1-ETO with a constitutively active tyrosinesarcoma. The inability of AML1-ETO to induce leukemia by itself
kinase correlated with the development of myeloblastic disease.is consistent with recent clinical data from patients with t(8;21)-
Similarly, recent studies from our own laboratory, as well ascontaining AML (Nucifora et al., 1993; Miyamoto et al., 1996;
others, have identified a high frequency of N-RAS and C-KITSaunders et al., 1997; Miyamoto et al., 2000). In these patients,
mutations in core bind factor leukemias (Beghini et al., 2000).it is common to find persistent low numbers of AML1-ETO-
Coupled with the data from our murine model, these studies sug-expressingcells in theBMduringclinical remission.TheseAML1-
gest that altered growth factor signaling pathways are likely to beETO-expressing cells retain their capacity to differentiate to ma-
a frequent collaborating event in AML1-ETO mediated leukemo-ture cells of the myeloid, erythroid and B cell lineages, and can
genesis.persist within the patient for greater than 10 years. Thus, these
The occurrence of several T cell lymphoblastic lymphomascells are not leukemic, but rather appear to represent a preleuke-
mic population that must acquire additional mutations in order to in the AML1-ETO-expressing mice was an unexpected finding,
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monitored daily for evidence of disease and peripheral blood cell counts withconsidering the near complete absence of the activated allele in
a differential were performed every three weeks.normal T cells. Moreover, expression of the AML1-ETO fusion
protein was not detected in the majority of the T cell tumors ana-
In vitro activation of the conditional AML1-ETO allele
lyzed (4/5).Althoughwecannot rule out thepossibility thatAML1- BMcell from5-fluorouracil treatedAML1-ETO-stop/micewere infectedwith
ETO expression was extinguished in these tumors, its absence a MSCV retrovirus (Persons et al., 1997) engineered to express Cre from the
suggests that the formation of these T cell tumors may be an LTR followed by the encephalomyocarditis virus internal ribosome entry site
and a cDNA encoding the enhanced green fluorescent protein (MSCV-Cre-indirect consequence of AML1-ETO induced T cell toxicity. It is
IRES-GFP). Infection of BM cells was carried out by coculturing with retroviralimportant to note that the predominant tumor type induced fol-
producer cell lines (Persons et al., 1997), and after 10 days in culture, GFP-lowing ENU treatment of normal mice is T cell lymphoma (Breuer
expressing cells were sterilely sorted and subsequently expanded.et al., 1991). In addition, it has been established that pI-pC treat-
ment induces a rapid decrease in the number of thymoctyes by Hematopoietic progenitor assays
over 50% (Kuhn et al., 1995). The T cells that remain following pI- Hematopoietic cells were cultured in methylcellulose-containing media as
pC treatment and activation of the AML1-ETO-stop allele may previously described (Okuda et al., 1996) using MethoCultGF M3434 media
(StemCell Technologies, Vancouver, British Columbia, Canada), which con-have an increased susceptibility to transformation as a conse-
tains 50 ng/ml murine stem cell factor, 10 ng/ml murine interleukin (IL)-3, 10quence of compensatory proliferation. Experiments to achieve
ng/ml human IL-6, and 3 units/ml human erythropoietin. CFU-S12 were as-lineage specific activation of the AML1-ETO-stop allele in T cells
sessed by injecting intravenously 2–5 104 BM cells from untreated or pI-pC
through the use of the lck-Cre transgene should help to further treated AML1-ETO-stop/Mx1-Cre/mice into recipient mice thathad been
define the role of this fusion protein in the development of these previously exposed to a split dose of 950 cGy. Transplanted mice were sacri-
T cell tumors. ficed 12 days postinjection and spleen colonies were counted, and then ex-
cised and analyzed for expression of AML1-ETO.In summary, this murine model of t(8;21)-containing AML
should serve as a powerful tool to aid in the determination of the
ENU mutagenesisspectrum of mutations that cooperate with AML1-ETO to induce
5- to 10-week-old AML1-ETO-stop/Mx1-Cre/ mice were treated with pI-leukemia. Moreover, this model should prove valuable in the as-
pC as described above, and then 6 days after the last dose were injected with
sessment of novel therapies targeted toward either the AML1- 1	g of human G-CSF (NEUPOGEN; Amgen, Thousand Oaks, CA) subcutane-
ETO chimeric oncoprotein, interactive partners proteins such as ously for4consecutivedays.On thefifthday,micewere injected intraperitone-
the nuclear corepressors complex, or integral components of the ally with a single sublethal dose of 50 mg/kg N-ethyl-N-nitrosourea (ENU;
Sigma, St. Louis, MO).downstream signaling pathway altered by expression of AML1-
ETO. Lastly, the experimental strategy employed to make the
Western blot and immunophenotypic analysisAML1-ETO conditional allele should have broad applicability in
Westernblotwasperformedaspreviouslydescribed (Okudaetal., 1998)usingthe generation of other models of human malignancies. Through
affinity purified AML-1 N-terminal peptide antiserum, affinity purified ETO
the use of a conditional transcriptional stop cassette, the expres- N-terminal peptide antiserum, or commercial antibodies against p53 (Ab-7,
sion of dominantly acting oncogenes or tumor suppressors can Oncogene Research Products, Boston, MA), p21 (c-19, Santa Cruz Biotech-
beregulated inbothatemporaland lineage-specificmanner.This nology Inc., Santa Cruz, CA), p16INK4A (M-156, Santa Cruz Biotechnology Inc.),
p19Arf (Abcam Limited, Cambridge, UK), CDK4 (H-22, Santa Cruz Biotechnol-levelofcontrol provides theability to accuratelydirectexpression
ogy Inc.), Cyclin D2 (M-20, Santa Cruz Biotechnology Inc.), Actin (c-11, Santaof these genes to the appropriate cellular targets needed to
Cruz Biotechnology Inc.), and phosporylated pRb (Cell Signaling Technology,model the desired human neoplasm.
Beverly, MA). Cell surface antigens expression was detected using phyco-
erythrin-conjugated monoclonal antibodies (MoAb) from PharMigen (SanExperimental procedures
Diego, CA) to CD34, c-Kit, Sca-1, Gr-1, (Mac-1), B220, CD4, CD8, and
TER119.Generation of mice with a conditional AML1-ETO allele
To generate a conditional AML1-ETO allele, a targeting vector was con-
Histology and spectral karyotypingstructed in which a fragment of the human AML1-ETO cDNA, which encodes
Tissues were fixed in 10% buffered formalin, embedded in paraffin, and sections62 bp of AML1 exon 4, all of exon 5, and the entire fused portion of ETO, was
stained with hematoxylin and eosin or by the avidin-biotin-peroxidase methodinserted in frame into the murine AML1 exon 4 as previously described (Okuda
using anti-Myeloperoxidase, CD3, lysozyme (DAKO, Carpinteria, CA), and B220/et al., 1998). To efficiently inhibit expression of the fused AML1-ETO se-
CD45R (PharMingen, San Diego, CA) antibodies. Peripheral blood was collectedquences, we inserted a 1.5 kb DNA fragment containing a 1.3 kb transcription
in 10 mmol/L EDTA and smears stained with Wright-Giemsa. Multicolor spectraltermination stop cassette flanked by loxP sites (Lakso et al., 1992) (Life Tech-
karyotyping was performed using standard methodologies.nologies Inc, Gaithersburg, MD) into an SfiI site into AML1 intron 3. This cas-
sette contains a strong SV40 polyadenylation sequence, and thus prevents
Transplantation analysisthe generation of full-length transcripts. Although the use of this stop cassette
Tumor cells from AML1-ETO-stop/Mx1-Cre/ mice (2.5–6 106) were ex-resulted in a complete abrogation of the production of AML1-ETO protein,
panded in short term cultures in the presence of cytokines (1 week) and thentrace levels of an alternatively processed AML1-ETO transcript were detected
transplanted into either syngeneic or C.B-17 SCID mice. For transplants intoby RT-PCR analysis. This trace transcript resulted from low levels of splicing
syngeneic mice, cells were injected intravenously into both sublethally irradi-of AML1 exon 3 into the stop cassette and then to the fused AML1 exon 4.
ated (450 cGy in a split dose) or nonirradiated recipients. Injections into SCIDImportantly, however, this chimeric transcript did not result in the production
mice were similarly performed into irradiated (350 cGy) or nonirradiated mice.of detectable protein. AML1-ETO-stop/ ES cell clones with undifferentiated
However, to expand our analysis, nonirradiated SCID mice were injected bothmorphology and normal karyotypes were injected into C57BL/6 blastocysts
intravenously and subcutaneously. Recipient mice were 5 to 28 weeks of ageandmalechimeraswerebredwithC57BL/6females toachievegermline trans-
at the time of transplantation. Mice were monitored every day for sickness andmission.
sacrificed when moribund.Double transgenic AML1-ETO-stop/Mx1-Cre/ mice were generated
by crossing these mice with a line transgenic for an Mx1-Cre gene (kindly pro-
vided by Dr. Werner Mu¨ller, University of Cologne, Germany) (Kuhn et al., RT-PCR and sequence analysis
For RT-PCR analysis, RNA was extracted and amplified as previously de-1995). Expression of Cre was induced by injecting mice intraperitoneally with
250 	g of polyinocinic-polycytidylic acid (pI-pC, Sigma, St. Louis, MO) three scribed (Okuda et al., 1998). Detection of AML1-ETO mRNA was performed
using primers to murine AML1 exon 3 (5-ACTTCCTCTGCTCCGTGCTA-3)times at 2-day intervals as previously described (Kuhn et al., 1995). Mice were
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gene in myelodysplastic syndrome and their functional implications in leuke-and human ETO (5-TTGAGTAGTTGGGGGAGGTG-3). Amplification was
mogenesis. Blood 96, 3154–3160.carried out with parameters of 2 min at 94
C for denaturation followed by 30
cycles of 1 min at 94
C, 1 min at 62
C, 40 s at 72
C, ending with 6 min at 72
C. Kohzaki, H., Ito, K., Huang, G., Wee, H.J., Murakami, Y., and Ito, Y. (1999).
For mutation screening of N-ras, H-ras, K-ras, and AML1, individual exons Block in granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but
were amplified and directly sequenced using standard methodologies. For not by highly expressed Bcl-2. Oncogene 18, 4055–4062.
p53, sequence analysis was performed on amplified mRNA. The sequence of
Kojima, K., Yasukawa, M., Ishimaru, F., Dansako, H., Matsuo, Y., Kimura, Y.,the primers used for amplification and sequencing are included in the Supple-
Nawa, Y., Hara, M., and Harada, M. (2000). Additional translocationmental Data at http://www.cancercell.org/cgi/content/full/1/1/63/DC1.
(8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous
leukemia in the blastic phase. Br. J. Haematol. 110, 720–722.Acknowledgments
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